13492-01-8
13492-01-8 structure
- Name: trans-2-Phenylcyclopropylamine hemisulfate salt
- Chemical Name: trans-2-Phenylcyclopropylamine hemisulfate salt
- CAS Number: 13492-01-8
- Molecular Formula: C9H12NO2S0.5
- Molecular Weight: 182.23
- Catalog: analytical chemistry Standard Pharmacopoeia Standards and Magazine Standards
- Create Date: 2018-03-30 08:00:00
- Modify Date: 2026-07-10 11:26:09
-
Tranylcypromine hemisulfate is an irreversible, nonselective MAO inhibitor used in the treatment of depression.
| Name | trans-2-Phenylcyclopropylamine hemisulfate salt |
|---|---|
| Synonyms |
TRANYLCYPROMINE HEMISULFATE SALT
pnate (1R,2S)-rel-2-Phenylcyclopropanamine Disulfate Tranylcypromine Sulfate tranylcyprominesulphate Tranylcypromine (hemisulfate) trans,d,l-2-phenylcyclopropylaminesulfate 2-phenyl-cyclopropanamintrans-(+-)-cyclopropanaminsulfate(2:1) phenylcycloprominesulfate rel-(1R,2S)-2-phenylcyclopropan-1-amine hemisulfate (1R,2S)-rel-2-Phenylcyclopropanamine Sulfate TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE TRANYLCYPROMINE HEMISULFATE Tranylcypromine rans-2-Phenylcyclopropylaminehemisulfatesal trans-2-Phenylcyclopropylamine hemisulfate salt CAS -1 TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE SALT 2-phenyl-cyclopropylaminsulfate,trans-(+-)-cyclopropylamin(2:1) 1-amino-2-phenylcyclopropanesulfate trans-2-Phenylcyclopropanamine hemisulfate Tranylcypromine, MAO inhibitor Tranylcypromine sulfate (+-)-trans-2-phenylcyclopropylaminesulfate(2:1) Tranylcypromine Sulfate|||Tranylcypromine (hemisulfate) tranylcyprominesulfate |
| Description | Tranylcypromine hemisulfate is an irreversible, nonselective MAO inhibitor used in the treatment of depression. |
|---|---|
| Related Catalog | |
| In Vitro | Tranylcypromine (10 nM to 10 µM) exerts neuroprotective effects against toxicity induced by human Aβ(1-42) oligomers independently from the presence of glial cells[1]. Tranylcypromine (100 μM) significantly protects RGCs from glutamate neurotoxicity-induced apoptosis as well as apoptosis induced by oxidative stress. Tranylcypromine promotes mitogen-activated protein kinase 12 (p38 MAPKγ) expression under conditions of glutamate (Glu)-induced stress. Besides, tranylcypromine contributes to RGC survival via alterations of p38 MAPKγ activity[3]. |
| In Vivo | Tranylcypromine treatment significantly and substantially reduces the lesion size and improves generalized hyperalgesia in a dose-dependent fashion in mice with induced endometriosis. In addition, tranylcypromine treatment results in reduced immunoreactivity to biomarkers of proliferation, angiogenesis, and H3K4 methylation, leading to arrested EMT and lesion growth[2]. Tranylcypromine (500 mM) injection exerts neuroprotective effects within intracellular apoptotic signaling pathways and suppresses morphologic changes in the retina of the rat, suppresses caspase 3 activity and recovers p38 MAPKγ expression in the retina after NMDA-induced injury, and enhances RGC survival after retinal injury via the attenuation of NMDA neurotoxicity[3]. Tranylcypromine (10 µg/g) causes an approximate and significant doubling of labeled cells in the combined brain regions examined, as detected by BrdU immunohistochemistry. Tranylcypromine causes the greatest increase in cell proliferation in the cerebellum[4]. |
| Animal Admin | Briefly, the rats are anesthetized with an intraperitoneal injection of a 1:1 mixture of xylazine hydrochloride (4 mg/kg) and ketamine hydrochloride (10 mg/kg). Then, the pupil is dilated with phenylephrine hydrochloride and tropicamide eye drops, and 20 nmol NMDA with or without tranylcypromine is injected into the vitreous cavity. To assess the inhibitory effect of mitogen-activated protein kinase (MAPK), 100 nmol BIRB796 is intravitreally injected at the same time of NMDA injection. The injections are performed under a microscope using a 33-gauge needle connected to a microsyringe; the needle is inserted approximately 1.0 mm behind the corneal limbus. Next, either PBS (vehicle control) or 500 mM tranylcypromine (1000 nmol) mixed with 10 mM NMDA (20 nmol) in a total volume of 2.0 μL is injected into the vitreous cavity. |
| References |
| Density | 1.065g/cm3 |
|---|---|
| Boiling Point | 218.3ºC at 760mmHg |
| Molecular Formula | C9H12NO2S0.5 |
| Molecular Weight | 182.23 |
| Flash Point | 90.8ºC |
| PSA | 135.02000 |
| LogP | 4.83100 |
| Vapour Pressure | 0.127mmHg at 25°C |
| Storage condition | 2-8°C |
| Water Solubility | Soluble in water; very slightly soluble in ethanol (96%) and in ether . |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H300-H311-H331 |
| Precautionary Statements | P261-P264-P280-P301 + P310-P311 |
| Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | T: Toxic; |
| Risk Phrases | R23/24/25 |
| Safety Phrases | 36/37/39-45 |
| RIDADR | UN 2811 6 |
| WGK Germany | 3 |
| RTECS | GZ2625000 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |